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Abstract
Mitochondria are important cellular organelles with key regulatory functions in 
energy production, oxidative balance, and calcium homeostasis. This is especially 
important in the brain, since neurons require a large number of functional mito-
chondria to supply their high energy requirement, mainly for synaptic processes. A 
decrease in the activity and quality of mitochondria in the brain, particularly in the 
hippocampus, is associated with normal aging and a large number of neurodegen-
erative diseases compromising memory function. Although synaptic and cognitive 
dysfunction is multifactorial, growing evidence demonstrates that mitochondria 
play a key role in these processes and suggests that maintaining mitochondrial 
function could prevent these age-dependent alterations. In this chapter, we will 
discuss the hippocampal mitochondrial dysfunction present in aging and how these 
defects promote age-associated synaptic damage and cognitive impairment. We 
will summarize evidence that shows how neurodegeneration can be accelerated or 
attenuated during aging by modulating mitochondrial function.
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1. Introduction
Aging is an extensively studied process, identifying a growing interest in how 
and why cognitive processes are affected from a neurobiological approach [1]. 
Aging is a multifactorial biological process, characterized by deterioration of physi-
ological and cellular functions including brain function [2], where age is the main 
risk factor for the development of pathologies such as cancer, diabetes, cardiovas-
cular disorders, and neurodegenerative diseases [3]. Cognitive deterioration occurs 
during aging, where reasoning, attention, and memory, among other processes, 
decrease gradually with the age [4]. Cellular senescence and alterations to mito-
chondria and in proteolytic systems are considered hallmarks of aging [3], where 
one of the most studied is the mitochondria [5]. In fact, mitochondrial dysfunction 
has been directly associated with the aging phenotype and the majority of diseases 
that lead to cognitive damage.
Over the last decades, a great interest has arisen regarding mitochondrial struc-
ture and function due to its relation with the aging brain [5]. Mitochondria are 
organelles essential for energy production, whose size is usually 0.5–1 μm, composed 
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by two membranes, forming the intermembranous space and the mitochondrial 
matrix [6]. The outer membrane contains many copies of the transport protein porin 
(or voltage-dependent anion-selective channels (VDAC)), which allows the passage 
of molecules with a maximum weight of 5 KDalton (KDa), and the inner membrane 
forms numerous invaginations, tubular structures, called cristae [6]. Mitochondria 
are capable of remodeling their architecture through fission and fusion processes, 
allowing morphological adaptation to different situations [6]. Fission is essential for 
mitochondrial duplication and is necessary for mitophagy, allowing dysfunctional 
mitochondrial sections to be recycled. Fusion allows mitochondria to interconnect, 
allowing damaged mitochondria to maintain their function. However, fission-fusion 
processes are interrupted during aging, generating damaged mitochondria [7].
Mitochondria have a small circular genome called mtDNA, which encodes 22 
tRNAs, 2 mitochondrial rRNAs, and 13 subunits of the electron transport chain 
(ETC) [8]. mtDNA can be damaged by exposure to reactive oxygen species (ROS), 
chemical carcinogens, and ionizing radiation affecting the mitochondrial function; 
changes are also observed during aging [9]. The internal mitochondrial membrane 
contains the ETC, responsible for generating ATP. ETC is formed by five protein 
complexes; complex I (NADH dehydrogenase) receives electrons of NADH which 
pass through the ETC via oxidation-reduction reactions forming an electrochemical 
gradient that allows the formation of ATP. In addition, FADH2 donates its electrons 
to complex II (succinate dehydrogenase) performing the same action for ATP gen-
eration but at lower production levels [10]. As a secondary product, the ETC forms 
ROS, specifically by complexes I and III, but its production is controlled by antioxi-
dant enzymes [11]. Therefore, in normal conditions ROS production is moderate, 
providing certain physiological roles [11]; however, during aging ROS accumulation 
causes biological damage known as “oxidative stress” [12].
In the past, mitochondria have always been highlighted for its role in ATP 
production; however, another key function is to maintain intracellular calcium 
homeostasis [13]. The outer mitochondrial membrane is permeable to ions and 
~5 KDa metabolites because its lipid bilayer has transmembrane proteins that 
form the mitochondrial permeability transition pore (mPTP). mPTP opening and 
closing dynamics regulates the concentration of calcium [13]. However, in condi-
tions of high calcium concentrations, permanent mPTP opening generates massive 
transport of ions and small molecules <1.5 KDa through the membrane, causing 
increased ROS production, inhibition of the ETC, and mitochondrial swelling, 
which finally results in the release of pro-apoptotic factors and cell death [14].
In this chapter we will discuss the mitochondrial alterations observed in the 
brain during aging, focusing on mitochondrial functions including redox balance, 
bioenergetics, and calcium homeostasis, and its implications in the aging process. In 
addition, we will discuss the contribution of mitochondrial dysfunction to synaptic 
failure and cognitive impairment. Finally, we will summarize potential treatments 
that have been proposed to prevent or attenuate the loss of mitochondrial function 
that could be used as potential antiaging treatment.
2. Oxidative stress: the main characteristic of normal aging
Aging is a complex process that involves both intrinsic and extrinsic factors [3]. 
Several researches showed that the reduction of synaptic function during aging 
could be related to increased oxidative stress and mitochondrial dysfunction [15, 16]. 
The latter involves decreased production of energy and redox balance, activation 
of nitric oxide synthase, and an abundant generation of free radicals; meanwhile 
increased ROS production impairs neuronal function at advanced ages [17].
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Mitochondria have a pivotal role in ROS production; they are the main organelle 
producer of species such as hydrogen peroxide (H2O2), superoxide anion (O
2−), and 
hydroxyl radicals (OH−) [18]. ROS comprise all molecules derived from oxygen, can 
exist independently, and contain one or more unpaired electrons in their orbitals 
[19]. Normally, mitochondria generate ROS as a result of adequate function of the 
ETC by complexes I and III in OXPHOS to produce ATP. Likewise, electrons that 
escape mitochondrial ETC can reduce oxygen to form O2− [20]. Additionally, H2O2 
is more stable than O2− and can diffuse freely through the membranes to the cytosol 
or nucleus, causing oxidative damage to many cellular compartments [21].
The mitochondrial ROS produced in normal conditions have important physi-
ological roles in maintaining cell homeostasis, participate as signaling molecules, 
and are also related to the regulation of cell survival [22]. In contrast, excessive ROS 
production promotes cellular damage [23]. For example, recent evidence suggests 
that higher mitochondrion-derived ROS result in enhanced formation of Aβ, an 
effect that is prevented with the use of antioxidants that rescue mitochondrial func-
tion in cellular and animal models of Alzheimer’s disease (AD) [24]. This suggests 
that higher ROS generation mediated by mitochondria is involved in early stages of 
age-associated diseases and during aging [25].
Cells maintain a balance between free radicals by the action of antioxidants mol-
ecules, which neutralize or remove them [22]. Cells are equipped with a variety of 
defense mechanisms to remove ROS, including antioxidant enzymes that facilitate 
antioxidant reactions and decompose ROS [26]. Among the antioxidant enzymes 
are glutathione reductase (GR), glutathione peroxidase (GPx), and catalase (CAT). 
In addition, superoxide dismutases (SODs), such as copper-zinc-superoxide 
dismutase (CuZnSOD) and manganese superoxide dismutase (MnSOD), help the 
dismutation of superoxide radicals to generate H2O2, which is further removed by 
CAT and GPx enzymes [26]. Altogether, these antioxidant defenses regulate the 
amount of ROS, preventing accumulation and oxidative stress [27].
Oxidative stress occurs when the antioxidant defense mechanisms are unable to 
neutralize free radicals in the cell. This imbalance between the production of oxida-
tive molecules and the antioxidant defense leads to an accumulation of ROS, which 
oxidize and produce damage to lipids, proteins, and DNA molecules. Similarly, ROS 
could alter many cell compartments, for example, promoting peroxidation of lipid 
membranes and inactivation of enzymes by oxidation [28].
In oxidative stress conditions, the concentration of ROS increases transiently or 
chronically, altering the cellular metabolism and its regulation [23]. Interestingly, 
these elements are implicated in the aging process, the mitochondrial free radical 
theory of aging (MFRTA) being the most accepted theory to explain the age-associ-
ated degeneration [29]. This theory exposed by Harman proposes that mitochondria 
play a central role in aging and indicates that aging is the product of accumulated 
damage caused by mitochondrial ROS in the cells and tissues of organisms [30, 31]. 
Nevertheless, this theory has also been questioned, since aging is a multifactorial 
biological process and not just the consequence of a unique factor [32]. Thus, the 
mitochondrial theory of aging is relevant since these organelles are energy sources 
for cells and coordinate important processes such as apoptosis. During aging, 
accumulation of mtDNA mutations is increased, the mitochondrial genes related 
to energy production become progressively less active, and the mitochondria are 
observed as fragmented, producing less energy [33]. The brain is particularly 
susceptible to oxidative damage being the most aerobically active organ in the body 
due to its high metabolism [34]. The brain is generally in a redox balance; however, 
the high production and accumulation of ROS accompanied by a reduction in the 
antioxidant defense system plays a key role in aging, causing damaging effects 
due to the large number of potential harmful intermediates that cause neuronal 
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dysfunction [3, 35]. In turn, increased oxygen radical-induced oxidative damage 
during aging leads to significant changes in brain mitochondrial function [29]. 
Therefore, oxidative stress is implicated in aging and a wide range of age-related 
pathologies, such as AD and Parkinson’s disease (PD), among others [3, 16, 36].
In the aged brain, a reduction in normal antioxidant defense machineries is 
observed, which increases the brain’s susceptibility to the harmful effects of oxida-
tive molecules [27, 37]. In addition to this, mitochondrial dysfunction contributes 
to ROS overproduction. It is important to emphasize that a decrease in the activity 
of oxidative enzymes accompanied by excessive production of oxidant molecules 
during aging is the main toxic mechanism that explains the neurodegeneration 
observed at an advanced age [27, 37]. Since mitochondria are the main source of 
ROS production, they are in turn more exposed to oxidative damage at a faster 
and stronger rate than other organelles and cell compartments [16]. Moreover, the 
mitochondrial antioxidant system is less active than the antioxidant systems of 
other organelles, a feature that increases with age [5]. These mitochondrial “defects” 
can greatly affect several cellular processes that contribute to the aging phenotype 
[38]. Therefore, age is an important risk factor that increases the susceptibility 
of mitochondria, making them more vulnerable to oxidative stress, resulting in 
a vicious cycle of mitochondrial dysfunction and more oxidative damage [5, 33]. 
Mitochondria should be considered as a key factor in the development of age-
related neurodegeneration, and therefore therapeutic strategies such as mitochon-
drial protectors or antioxidants that improve mitochondrial function could be used 
to prevent or delay aging.
3. Bioenergetic failure during aging
One of the main functions of mitochondria is energy production in the form of 
ATP through OXPHOS [39]. The main substrate of neurons is glucose. Through the 
glycolytic pathway, the cell generates only two ATP molecules per glucose molecule; 
however in this pathway two pyruvate molecules are produced. These molecules 
then enter the mitochondria to be oxidized in the tricarboxylic acid (TCA) cycle 
producing NADH and FADH2, which in turn enter the ETC to produce high 
amounts of ATP by OXPHOS [40]. Electrons from NADH and FADH2 are trans-
ferred through four complexes to molecular oxygen, pumping protons to the inter-
membrane space, which form a proton gradient that generates the mitochondrial 
membrane potential (Δψm). This Δψm is fundamental for adequate mitochondrial 
function, mainly for ATP synthesis by the ATPase complex [39].
Due to the importance of mitochondrial energy production, failures in 
mitochondrial bioenergetics are related to several neurological diseases such as 
amyotrophic lateral sclerosis (ALS) [41] and several age-associated neurodegenera-
tive disorders such as AD [42]. A mitochondrial failure can be caused by either 
a dysfunction in the OXPHOS complexes or by mutations in the mtDNA, which 
encodes for 13 proteins that makes the different subunits of the ETC complexes. 
Interestingly, mtDNA mutations produce a group of pathologies known as primary 
mitochondrial disorders, characterized by neurological alterations. Thus, neurode-
generation is often related to mitochondrial dysfunction as a primary or secondary 
target, mediating the pathogenic events [43]. Since the main energy source in brain 
cells is glucose oxidation, the energy obtained from the mitochondrial OXPHOS 
system is vital to fulfilling their high basal energy requirement, including mainte-
nance of the membrane potential for the propagation of electric signals, reestablish-
ment of the ion balance after the action potential (Na+/K+ ATPase activity), vesicle 
recycling, and neurotransmitter release [44].
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Therefore, a deficit in ATP production can lead to neuronal damage and finally 
cell death, producing diverse defects in brain functions as occurs during normal 
aging, considered an important risk to the development of neurodegenerative dis-
ease [45]. An example of this is the glutamate-glutamine cycle, an essential process 
for the release of glutamate from the presynaptic terminal. Glutamate uptake occurs 
in astrocytes, where it is converted to glutamine and then transferred back to glu-
tamatergic neurons. For these processes to occur, the neuron requires ATP [46], as 
well as for the accumulation of glutamate in synaptic vesicles [47]. Therefore lower 
ATP levels will result in reduced glutamate release leading to decreased excitatory 
synapsis and consequently decreased synaptic plasticity as a result of altered long-
term potentiation (LTP) and long-term depression (LTD) [48].
In addition, AD is a neurodegenerative pathology where mitochondrial defi-
ciency is observed in oxidative phosphorylation, with defective OXPHOS enzymes 
[49]. Several studies showed decreased cytochrome c oxidase activity but an 
increase in mitochondrial mRNA for complex IV, which may be a compensatory 
response for the reduced cytochrome c oxidase activity [50, 51]. Also, there is a 
decrease in NADH dehydrogenase expression and an increase in complex III mRNA 
in AD patients [51]. These defects in the OXPHOS complex impede correct ATP 
production and increase ROS production [52], which could generate damage to 
mitochondrial proteins, activate the mPTP, and mutagenize the mtDNA, leading to 
defective OXPHOS. All these mitochondrial defects can ultimately contribute to the 
characteristic synapse loss in the neocortex and hippocampus of AD patients [53], 
which correlates with cognitive impairment and memory loss. Similarly, critical 
mitochondrial dysfunction has been associated with PD. Several mutations in pro-
teins that can directly or indirectly regulate mitochondrial activity and morphology 
have been described. Examples of this are PTEN-induced kinase 1 (PINK1) which 
induced mitochondrial autophagy during stress [54] and protein deglycase (DJ-1) 
which is a multifunctional protein that reacts against anti-oxidative stress [55]. 
These two proteins are localized in the mitochondria, while parkin, another protein 
that degrades dysfunctional mitochondria, translocates to damaged mitochondria 
[54]. The first evidence that mitochondria could be related to PD was published 
by Langston et al. in 1983 where they showed that the mitochondrial complex I 
inhibitor, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can cause acute 
and irreversible parkinsonian symptoms in humans [56]. Later, other mitochondrial 
toxins such as rotenone, which induces similar symptoms to MPTP, were described, 
leading to the development of a rotenone rodent model of Parkinson’s disease [57]. 
Other studies of postmortem tissue from PD patients showed defects in complex I, 
NADH dehydrogenase in the substantia nigra [58].
Interestingly, similar bioenergetic deficits present in neurodegenerative disease 
are also seen in normal aging. In this natural process, it is well known that a large 
number of mutations accumulate in the mtDNA in different tissues, such as the 
brain and the muscle, the tissues with most accumulation of mutations, possibly 
due to the higher energetic demand [59]. For example, in a study performed with 
humans between 49 and 92 years old, they showed an increase by 25% in the muscle 
fibers that exhibit abnormalities in mitochondrial ETC in 92-year-old individu-
als compared to 49 year olds [60]. Another study showed that a mouse with a 
deficiency for mitochondrial DNA polymerase γ (POLG) had an impaired proof-
reading ability, accumulated mtDNA mutations, and presented a premature-aged 
phenotype (hair loss, graying, kyphosis, reduced survival percentage, loss of bone 
mass, etc.) at the age of 9 months [61]. These mutations can lead to mitochondrial 
dysfunction associated with a deficient respiratory chain and a decrease in ATP 
production [62]. There is evidence that the brain of aged mice (26 months old) 
contains mutations in protein-coding regions that result in significant changes 
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in the complex I subunit ND5 and complex III subunit CytB [62]. These muta-
tions may limit correct assembly of these complexes, which correlates with their 
decreased activity during aging [62]. Other studies also showed downregulation of 
several genes coding for mitochondrial proteins in heart tissue, which correlated 
with a significant decrease in the respiratory capacity of mitochondria to oxidize 
substrates [63]. In liver tissue, there is a decrease in the respiratory control ratio and 
in ADP/oxygen (an index of ATP synthesis efficiency) in senescence-accelerated 
mice (SAMP8) mitochondria [64], suggesting that at 18 months of age, there is 
insufficient ATP for normal cell metabolism, which may be due to a dysfunctional 
energy transfer mechanism.
In the brain, it is widely known that with aging there is a decrease in the electron 
transfer activity accompanied by a decrease mainly in complexes I and IV [65, 66]. 
Several studies showed that complex IV activity is decreased in substantia nigra, 
hippocampal dentate gyrus, frontal cortex, and cerebellum during aging [67, 68]. 
A study performed with aged CD1 Swiss mice showed that NADH-cytochrome c 
reductase (complexes I and III) activity is the most affected during aging, decreas-
ing by 48% in old mice (18 months), while succinate-cytochrome c reductase 
activity (complexes II and III) remain unmodified with age, indicating selective 
impairment of NADH dehydrogenase activity (complex I) during normal aging 
[69]. Likewise, cytochrome oxidase (complex IV) activity is decreased by 13% 
in old animals [69]. Additionally, there is evidence of increased expression of 
mitochondrial genes for complexes I, III, IV, and V in 18-month-old mice in the 
hippocampus, medial prefrontal cortex, and striatum [70], suggesting a compensa-
tory mechanism that could induce overproduction of ETC proteins. However, this 
increased mRNA expression is not sustained over time, since 24-month-old mice 
have decreased expression of ETC complexes [70].
Another parameter that is altered during aging is the Δψm due to increased H+ 
permeability of the inner mitochondrial membrane and a consequent failure in 
maintaining the H+ electrochemical gradient [71]. There is evidence that there is 
a decrease in the membrane potential in the cortical and striatal mitochondria of 
33-month-old rats [72]. In the same way, a study in primary cultures of glial cells 
from the brain of young (4–6 months) and old (26–29 months) mice shows a decay 
in the Δψm in astrocytes [73].
Thus, mitochondrial bioenergetic failure is a hallmark of different diseases 
including neurodegenerative disorders. Interestingly, these same patterns of 
decreased ATP production, OXPHOS failure, and depolarization of the mito-
chondrial membrane are seen during aging, a natural process of everybody’s life. 
This makes the mitochondria an important player in all neurological degeneration 
related with aging, such as synaptic failure and cognitive impairment.
4. Age-associated calcium dysregulation
Calcium (Ca+2) is an ion that participates in a wide variety of functions in the 
cells of organisms, being an intracellular regulator of many physiological processes 
[74]. Intracellular calcium signals participate in the regulation of a large number 
of processes, which include gene expression, cell cycle stages, control of muscle 
contraction, autophagy, and cell death, among other functions, being a second 
intracellular messenger [74, 75].
In the central nervous system (CNS), Ca+2 plays a very important role in the 
neuronal synapse, mainly promoting exocytosis of the synaptic vesicles in the 
presynaptic region, meanwhile in the postsynaptic site is important for regulating 
the morphology of dendritic spines and spinogenesis [76, 77]. Calcium homeostasis 
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is fundamental for correct cellular function, and the mitochondria are structures 
important for maintaining the intracellular calcium concentrations [78]. They 
participate in the local regulation of cellular Ca+2 homeostasis, since it captures 
Ca+2 from the cytosol in response to ion fluxes through channels in both the inner 
and outer plasma membranes or by release of Ca+2 from the endoplasmic reticulum 
(ER) [79]. Thus, when the cytosolic concentration of calcium increases, mitochon-
dria capture and accumulate large amounts of the ion in order to control intracel-
lular concentrations. Therefore, for appropriate neuronal functioning, adequate 
parameters of intracellular calcium concentrations must be maintained [80]. 
Interestingly, aged brain neurons are incapable of regulating intracellular calcium, 
mainly due to dysfunctional mitochondria and increased oxidative stress [78, 81].
Mitochondrial dysfunction substantially contributes to biological aging [78]. 
In aging, oxidative stress affects mitochondrial function and, therefore, its role in 
Ca+2 homeostasis [78, 82]. When calcium homeostasis is altered, it has a detrimental 
role on the aging brain and is also associated with the development of neurode-
generative diseases [83]. Several studies showed that an increase of the Ca+2 affects 
synaptic communication, neurotransmitter release, and signal transduction, all this 
generating excitotoxicity and neuronal loss [84]. In addition, these alterations could 
also contribute to memory impairment [16, 84].
In this way, since the aging is associated with a marked cognitive decline, the 
calcium imbalance hypothesis proposed by Khachaturian turns out to be well 
accepted [85, 86]. This hypothesis proposes that changes in calcium regulation 
gradually modulate normal brain aging and, at the same time, increase their vulner-
ability to neurodegenerative diseases such as AD [87]. Calcium signaling depends 
of the transient elevation of its intracellular concentration. In brain cells, reduced 
regulation of calcium homeostasis is an early event during aging, altering multiple 
signaling pathways and affecting various molecular and cellular functions [88].
Due to their high buffering capacity, mitochondria are an essential component 
for maintaining calcium homeostasis, due to their involvement in the regulation of 
intracellular calcium signaling [89]. Also, other mitochondrial characteristics that 
facilitate its role in the regulation of calcium signaling is its structural plasticity 
produced by fusion and fission processes in the mitochondrial network, as well 
as its distribution within the neuron [90]. Aging affects mitochondrial dynamics 
leading to mitochondrial fragmentation and alterations to these functions [90]. 
Studies in mitochondria isolated from the cortex of aged animals exhibited more 
ROS production and mitochondrial swelling after increased Ca+2 loading than that 
of young animals [78]. Therefore, these findings suggest that the aging increased 
the sensitivity of the mitochondria to calcium overload, generating mitochondrial 
swelling [81]. Mitochondrial swelling results in the opening of the mPTP [91], 
and in aged animals, mPTP opening occurs prematurely, indicating reduced Ca+2 
buffering during aging [78, 81].
The mPTP is a large nonselective channel located in the inner mitochondrial 
membrane and communicates the mitochondrial matrix directly with the cyto-
plasm [81]. Their opening is activated by Ca+2, phosphate, ROS, increased pH, and 
magnesium (Mg+2) [92]. Transitory opening of mPTP allows the release of excessive 
calcium ions that accumulate in the mitochondria, but prolonged opening leads to 
the movement of ions and small molecules generating depolarization of the mito-
chondrial membrane and in turn releasing pro-apoptotic factors, which results in a 
reduction of ATP and finally causes cell death [81, 91].
The structure of mPTP is not completely clear. Experimental approaches have 
distinguished several protein components such as VDAC, the adenine nucleotide 
translocase protein (ANT), and the mitochondrial matrix protein cyclophilin D 
(Cyp-D) [91]. Recent research incorporates the F1FO subunits of ATP synthase, a 
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Figure 1. 
The mitochondrial functions are impaired during aging.
key enzyme of the OXPHOS complex, which participates in ATP production and 
maintenance of the membrane potential [91]. Interestingly, deregulation of this 
enzyme associated with aging has been reported, showing decreased expression 
of OSCP and in F1FO ATP synthase activity [81, 91]. These changes have also been 
observed in imaged brains that present age-related neurodegenerative pathologies 
[81, 91]. Cyp-D is a specific mitochondrial protein and generally considered to be 
a critical component of mPTP formation [91]. Several studies indicate that Cyp-D 
is the most important component facilitating mPTP formation, thus leading to 
decreased ATP production, increasing ROS generation, and eventually causing cell 
death [81, 91], although it is not yet completely clear how Cyp-D triggers mPTP 
formation [92]. The opening of mPTP dissipates Δψm, uncoupling the mitochon-
dria and causing swelling [91]. The expression of Cyp-D increases with age and 
is related to several age-associated neurological diseases such as AD [91, 93]. For 
example, Gauba et al. have reported that Cyp-D promotes the dysfunction of ATP 
synthase F1FO, in the mitochondria of aged brains, observing a significant increase 
in the expression of this protein with age [91]. In contrast, it has been observed that 
deletion of Cyp-D improves cognitive and mitochondrial functions in both aging 
and in neurodegenerative diseases [91, 93].
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The increased life expectancy and the high incidence of neurodegenerative 
diseases require a better understanding of the aging processes and the mechanisms 
associated with it. Thus, comprehension of the interactions between calcium 
homeostasis and calcium-dependent processes during aging can help in the design 
of more effective therapeutic strategies. Maintaining calcium homeostasis and 
controlling the opening of mPTP are important factors that can be considered as 
a potential therapeutic objective to maintain the quality of life during aging and 
prevent mitochondrial damage and progressive cognitive deterioration associated 
with age that contribute to the development of neurodegenerative diseases.
Figure 1 is a schematic representation of the main mitochondrial functions 
affected during normal aging. It shows increased oxidative stress as a result of a 
REDOX imbalance due to decreased activity of antioxidant enzymes and increased 
reactive oxygen species. It also shows the characteristic bioenergetics failure, as 
a consequence of diminished OXPHOS functioning, specifically by decreased 
activity of complexes I and IV of the ETC, which lead to reduced ATP production 
and, finally, calcium dysregulation, which leads to mitochondrial swelling due to a 
permanent opening of the mitochondrial permeability transition pore.
5. Mitochondrial dysfunction and cognitive impairment
Synaptic plasticity in the adult nervous system is a response to changes in the 
environment and synaptic activity, involving dendritic spine growth or retraction 
and synaptogenesis, which are believed to be responsible for learning and memory 
[94]. In the hippocampus, one form of synapse plasticity is LTP, which produces a 
stronger transmission for consolidation of long-term memory [95]. For this process, 
neurons need to synthesize proteins de novo at the dendritic spines where different 
neurotrophic factors play a key role [96]. An impairment in this process leads to 
neurodegeneration, as a result of the initial loss of synaptic structure and function 
and finally cell death [96].
The previously described mitochondrial dysfunction could be an important fac-
tor in synapse loss associated with cognitive decline observed during aging and in 
neurodegenerative disease [97]. Since mitochondria are present in axonal terminals 
and dendrite spines playing a critical role in calcium flux, ROS homeostasis, and 
ATP production in the synapses, this organelle is a key element for neuronal plastic-
ity [94]. In addition, mitochondrial transport to the synaptic regions is essential for 
the correct function of this neuronal network [98].
Multiple pathological conditions present cognitive impairment related with a 
mitochondrial dysfunction. For example, chronic kidney disease (CKD) patients 
with cognitive damage have increased oxidative stress and decreased antioxidant 
enzymes (SOD, CAT, GPx, and GSH levels in plasma) compared to CKD patients 
without cognitive impairment [99]. Also, patients with hypoxia, ischemia induced 
by a traumatic brain injury (TBI), and diabetes showed cognitive decline and dif-
ferent signs of mitochondrial impairment such as glutamate excitotoxicity, calcium 
overload, opening of mPTP (which dissipates the mitochondrial electrochemical 
gradient leading to cell death), and increased ROS levels [100–102]. Interestingly, 
pyramidal neurons in the cerebral cortex and hippocampus are more susceptible 
to this type of injury [103], suggesting that these cellular defects may affect mainly 
synaptic plasticity, learning, and memory.
In the context of neurodegenerative disease, mitochondrial impairment and 
oxidative stress are the target of Aβ neurotoxicity, promoting cognitive impairment 
in AD [104]. The degree of cognitive impairment in AD has been related to the 
amount of Aβ accumulated in mitochondria [105], resulting in a loss of the Δψm in 
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synaptic regions and ultimately leading to the characteristic synaptic loss observed 
in AD [106]. It has been suggest that Cyp-D can interact with Aβ contributing to 
synaptic perturbations. A Cyp-D deficiency can notably improve synaptic function 
and therefore improve learning and memory in an AD mouse model [107]. It was 
recently proposed that tau protein can regulate synaptic activity, affecting mito-
chondrial function and axonal transport [108], and post-transductionally modified 
tau can induce mitochondrial damage, leading to synaptic dysfunction [109]. In 
fact, hyper-phosphorylated tau impairs mitochondrial respiratory chain function, 
increases ROS levels, decreases the activity of detoxifying enzymes, and produces 
Δψm dissipation [108]. Thus, the accumulation of tau can lead to synaptic deficits 
and cognitive impairment [110].
Interestingly, cognitive decline is not only characteristic of disease and injury, 
since cognitive impairment is also observed during aging. During normal aging, it 
is well established that there is a reduction in the surface area and cortical thick-
ness, resulting in a volume loss in the whole brain, being the non-cortical regions, 
such as the hippocampus and striatum, more vulnerable to this age-related atrophy 
[111]. In this context, a study performed with Sprague-Dawley rats of 14, 18, 23, 
and 27 months of age showed changes in the volume of different brain parts using 
magnetic resonance imaging (MRI) [112]. In that study they showed enlargement 
of lateral ventricles and a decrease in the volume of the medial prefrontal cortex, 
hippocampus, and striatum in 27-month-old rats, which correlates with cogni-
tive deficiency. Twenty-three- and twenty-seven-month-old rats have decreased 
recognition memory and decreased spatial learning and memory [112]. Another 
common symptom of aging is cognitive fatigue (CF) characterized by an increase in 
the facility of becoming tired, lack of energy, and failure to sustain attention when 
performing cognitively demanding tasks with a high mental effort [113]. There is 
evidence of a correlation between the decreased connectivity strength of the neuro-
nal network established between the cortical and the striatum areas and a higher CF 
at an advanced age, suggesting that the cortical-striatal network plays a crucial role 
in the CF phenomenon [114].
In humans, similar cognitive decline is observed during aging, present as a 
deficit in episodic or declarative memory, spatial learning, working memory, and 
attention [115]. These processes are mainly dependent on an adequate function of 
the hippocampus. Structural and functional changes in the hippocampus are related 
to the severity and development of neurodegenerative disorders associated with 
cognitive decline. In fact, many of the cognitive deficits seen with aging can be rep-
licated in animal models with bilateral hippocampal damage [116]. The connection 
between dentate gyrus (DG) and the CA3 area of the hippocampus is responsible 
for the formation of new memories, and this is naturally decreased in the aged brain 
[117], with different biochemical modifications that affect its ability to generate and 
consolidate LTP [117]. Diverse studies have shown that during aging, the auto-
associative network of CA3 is strengthened, and the processing of new information 
coming in from the entorhinal cortex is weaker [118]. Thus, the stored information 
becomes dominant in contrast to the ability to encode new information [118]. Also, 
there is a decrease in gray matter volume, where age-related changes in the temporal 
lobe involve mainly changes in the hippocampus [4].
Also, different studies show high levels of tau in cerebrospinal fluid (CSF) 
during aging [119, 120]. For example, the characteristic hearing loss (HL) present 
in aging influences neurodegeneration by promoting tau pathology in CSF [120], 
which produces cognitive impairment via synapsis dysfunction and neuronal loss 
[110]. Other studies evidence the age-related impairment of executive functions, 
verbal and nonverbal cognitive switching (independent of gender, education, and 
IQ ), and the ability to focus attention and/or multitask [121, 122]. Studies have 
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shown that during aging, there is a reduction in inhibitory mechanisms in the CA3, 
where short-term plasticity and LTP are compromised [123]. Interestingly, mito-
chondria play a central role in LTP, enhancing mitochondrial gene expression [124], 
satisfying the ATP demand by producing changes in mitochondrial energy produc-
tion, and regulating calcium homeostasis by increasing calcium pump activity 
[125]. Also, there is evidence that mitochondrial dysfunction can lead to failure in 
connectivity of brain cortex producing cognitive impairment [126]. Thus, mito-
chondrial dysfunction during aging can be related with degeneration of synapses, 
triggering cell death.
In this mitochondrial context of aging, it is interesting that in brain regions 
highly associated with cognitive function, such as the hippocampus and cortex, 
there is a high amount of impaired mitochondria, with dysfunctional respiration, 
excessive ROS production, loss of Δψm, and decreased cytochrome c oxidase 
activity. Meanwhile mitochondria are less affected in areas of the brain that are 
less involved in cognitive abilities [105]. Therefore, mitochondrial function is a 
key component in cognition. It allows proper information processing through the 
brain network, being an important player in synaptic transmission. Mitochondrial 
dysfunction generates deficits in synapsis that trigger cognitive impairment in 
Figure 2. 
A synaptic failure leads to cognitive impairment in aging.
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neurodegenerative disease but also in natural aging. Thus, the understanding of 
these processes may be critical in these times where the aged population is increas-
ing; therefore, improving their quality of life is a priority.
Figure 2 above shows the synaptic effects of mitochondrial failure. In the 
presynaptic region, decreased mitochondrial activity diminishes ATP content, 
altering the exocytosis of synaptic vesicles. Also, increased ROS production induces 
lipid peroxidation, affecting glutamate and glucose transport. In the postsynaptic 
region, decreased mitochondrial activity disrupts calcium homeostasis, altering 
postsynaptic signaling. Besides, the increased ROS production and consequent 
lipid peroxidation impaired ion-motive ATPases. Figure 2 below schematizes that 
mitochondrial dysfunction at the CA1 of the hippocampus impaired synaptic 
transmission resulting in cognitive impairment.
6. Mitochondrial therapies as an antiaging treatment
Since mitochondrial dysfunction is a key event promoting aging, interventions 
that focus on maintaining or restoring the correct functioning of the mitochondria 
seem fundamental. For this purpose, two different experimental strategies could 
be used [127], physiological approaches or pharmacological approximations, which 
will be briefly summarized in this section.
From the physiological point of view, maintaining a lifestyle that includes 
recurrent physical exercise preserves mitochondrial function [127]. During aging 
a loss of age-associated muscle mass is directly related with decreased mitochon-
dria-dependent metabolic capacity, as well as with reduced mitochondrial bio-
genesis [128]. Biogenesis of new mitochondria is regulated by the transcriptional 
coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α), which also regulates redox balance and energetic function [129]. 
Interestingly, PGC-1α expression is decreased in aging reducing its signaling 
pathway and gene target [129], an effect that could be counteracted by exercise, 
demonstrating that exercise also increases mtDNA content in the muscle of aged 
rats [130]. In addition, exercise increases the expression of the CAT enzyme, 
reducing ROS levels [131]. Similarly, exercise promotes both fission and fusion 
events as indicated by upregulated levels of Fis1 and Mfn1 protein in the muscle 
tissue of old animals and by increased Mfn2 and Drp1 mRNA in the skeletal 
muscle of older women [132]. Finally, exercise could contribute to restoration of 
mitochondrial Ca+2 homeostasis, increasing the protein levels of mitochondrial 
Ca+2 uniporter (MCU) [132]. Thus, exercise during aging could promote the 
genesis of new mitochondria or could attenuate the mitochondrial dysfunction 
observed at an advanced age.
A second physiological approximation important for simulating mitochondrial 
function is caloric restriction, which has been demonstrated in different models 
that are able to reduce the age-related phenotype and to increase lifespan [133]. The 
beneficial effects of caloric restriction are directly associated with the bioenergetic 
defects observed in aging, activating ATP production through fatty acid metabo-
lism [134]. Mechanistically, caloric restriction increases the activity of complexes 
I, III, and IV of the ETC, as well as MnSOD, which results in increased ATP and 
reduced ROS levels [135]. Likewise, caloric restriction enhances Ca+2 mitochondrial 
buffering, decreasing Cyp-D levels [135]. Therefore, regulating caloric ingestion is 
possible for maintaining mitochondrial activity during aging.
Mitochondrial function can also be regulated pharmacologically, for example, 
through the administration of polyphenols such as resveratrol, green tea, and red 
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wine [127, 136]. Specifically, they act by promoting mitochondrial OXPHOS and 
activating cellular antioxidant mechanisms [137]. Another possibility is the use 
of antioxidant compounds such as MitoQ , an electron scavenger that prevents the 
formation of mitochondrial free radicals [138]. Similarly, α-tocopherol (MitoVitE), 
α-phenyl-tert-butylnitrone (MitoPBN), the piperidine nitroxide MitoTEMPOL, the 
antioxidant SkQ1, and elamipretide (SS-31) enter and accumulate in the mitochon-
dria preventing oxidative stress and preserving mitochondrial function [139, 140]. 
The numerous studies probing the clinical efficacy of these compounds validate 
the importance of mitochondria in aging [139]. To promote the natural antioxidant 
effect in the cell, treatment with N-acetylcysteine, vitamin, C and other physiologi-
cal antioxidant molecules have also been shown to be effective as palliative treat-
ment of senescence [141, 142].
It is also important to highlight the positive effects induced by the direct admin-
istration of fatty acids including omega-3 fatty acid α-linolenic acid, due to studies 
in vivo that have shown its capacity to extend lifespan [143]. This could be a con-
sequence of increased β-oxidation, which results in higher mitochondrial energy 
production, by increasing mitochondrial biogenesis or by reducing oxidative stress 
[144]. Finally, we will mention the effects of Metformin, a drug commonly used 
for the treatment of type 2 diabetes. Metformin has a hypoglycemic effect in the 
plasma and promotes increased insulin sensibility by a mechanism that remains 
unclear [145]. However, favorable effects have been observed, where DNA dam-
age and inflammation are prevented, impeding cellular damage by reducing ROS 
production [146].
Therefore, these approaches highlight the key role that mitochondrial function 
play during aging, where correct mitochondrial activity could extend lifespan, 
whereas metabolic alterations could compromise mitochondrial function, acceler-
ating the aging phenotype.
7.  Future directions: importance of synaptic mitochondrial dysfunction 
in aging
It is now known that the mitochondria have a fundamental role during the 
aging process. In neurons, the mitochondria are classified into two groups 
according to their localization, such as synaptic and non-synaptic mitochondria. 
Non-synaptic mitochondria are distributed throughout the cell body and in the 
neural prolongations, meanwhile synaptic mitochondria are exclusively found in 
synapses, both at the pre- and postsynaptic level [147]. Thus, it is not surprising 
that synaptic mitochondria, which have a higher energy requirement in order to 
sustain synaptic activity, present functional differences compared to non-synaptic 
mitochondria. For example, synaptic mitochondria have higher peroxide produc-
tion than non-synaptic ones [148]. During aging, it seems that these differences 
are accentuated between these two mitochondrial populations. Aged cortical 
synaptic mitochondria present decreased oxidative capacity and higher suscepti-
bility to calcium overload, in contrast to non-synaptic mitochondria that preserve 
their respiratory capacity [16]. Similarly, we observed that hippocampal synaptic 
mitochondria fail previous to non-synaptic mitochondria during aging and suffer 
premature mitochondrial swelling with age, contributing hippocampus-dependent 
memory loss (manuscript in preparation). Thus, maintaining adequate function 
of synaptic mitochondria seems to be the new challenge in order to attenuate the 
aging phenotype, reducing the synaptic and cognitive failure characteristics of 
older individuals.
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8. Conclusions
Taken together, the evidence presented in this chapter strongly suggests a 
close relationship between mitochondrial function and a wide range of processes 
associated with aging. In general, it is possible to propose an age-dependent decline 
observed in several organs such as the brain correlated with a loss of mitochondrial 
activity, generating a bioenergetic deficit and redox imbalance that promote oxida-
tive stress. This promotes additional mitochondrial fail, affecting cellular calcium 
homeostasis, critical for neurons due to its important roles in the synapses. Thus, 
synaptic defects conduce to cognitive impairment. Finally, we propose that the 
synaptic mitochondria are a critical mitochondrial pool to preserve synaptic com-
munication despite the passing of the years.
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